Competing interests
DIAZ, MINOR, EMD
This work was supported by Eli Lilly and Company. S. Estrem, I. Gueorguieva, M. Man, and J. Liu are full time employees and minor stockholders of Eli Lilly and Company. L. Ghandi was a full time employee of Eli Lilly and Company at the time of this work and is minor stockholder of Eli Lilly and Company, has received consultancy fees from Pilant Therapeutics, 28–7 Therapeutics, Riva Therapeutics, and Eli Lilly and company, has received speaker's bureau honoraria from Tempus, is on the advisory board for Beigene, Bristol-Myers Squibb, Mersana, Eisai, Xilio, and Tentarix, and is on the board of directors for Bright Peak Therapeutics an Neximmune. Y. Zhao, and S. Guba were full time employees and minor stockholders of Eli Lilly and Company at the time of this work. S. Guba has also received medical writing support from Eli Lilly and Company. K.A. Benhadji owns a patent with and is a minor stockholder of Eli Lilly and Company. E. Avsar is a full time employee of Eli Lilly and Company and a minor stockholder in Eli Lilly and Company and BMS, and was a full time employee of BMS at the time of this work. W. H Lin was an employee of BMS when this work was performed. E. Nadal has received grants or research funding from Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Roche, and Merck Serono, and has received speaker's bureau honoraria from Roche, Bristol Myers Squibb, Merck Sharp Dohme, Merck-Serono, Sanofi, Pfizer, Eli Lilly, Amgen, Boehringer-Ingelheim, AstraZeneca, Takeda, Sanofi, Janssen, Qiagen and Bayer. S. Patel is an advisory board member for Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly and Company, Jazz, Genentech, Illumina, Merck, Pfizer, Rakuten, and Tempus. S. Patel's university receives research funding from Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly and Company, Fate Therapeutics, Iovance, Merck, Pfizer, Roche/Genentech, and SQZ Biotechnologies. M. Saleh received medical writing support from Eli Lilly and Company. S. Antonia has been a consultant or advisory board member for Achilles Therapeutics, Amgen, Bristol-Myers Squibb, Celsius Therapeutics, G1 Therapeutics, Glimpse, Guardian Bio, GSK, Immutep, Memgen, Merck, RAPT Therapeutics, Shoreline, Taurus, Xilis, has been on the data safety monitoring board for EMD Serano, is a stockowner of Guardian, Shoreline, and RAPT Therapeutics, and has received travel reimbursement from RAPT Therapeutics. I. Ales Diaz, M. Ochoa-de-Olza, and S. Ponce Aix have nothing to declare.